ABSTRACT
Background Optimum formulation of Biological E’s CORBEVAX™ vaccine that contains protein sub unit of Receptor Binding Domain (RBD) from the spike protein of SARS-COV-2 formulated with aluminum hydroxide (Al3+) and CpG1018 as adjuvants was selected in phase-1 and 2 studies and proven to be safe, well tolerated and immunogenic in healthy adult population. In the current study, additional data was generated to determine immunogenic superiority of CORBEVAX™ vaccine over COVISHIELD™ vaccine and safety in larger and older population.
Methods This is a phase III prospective, single blinded, randomized, active controlled study (CTRI/2021/08/036074) conducted at 20 sites across India in healthy adults aged between 18-80 years. This study has two arms; immunogenicity arm and safety arm. Participants in immunogenicity arm were randomized equally to either CORBEVAX™™ or COVISHIELD™ vaccination groups to determine the immunogenic superiority. Healthy adults without a history of Covid-19 vaccination or SARS-CoV-2 infection, were enrolled.
Findings The safety profile of CORBEVAX™ vaccine was comparable to the comparator vaccine COVISHIELD™ in terms of overall AE rates, related AE rates and medically attended AEs. Majority of reported AEs were mild in nature, and overall CORBEVAX™ appeared to cause fewer local and systemic adverse reactions/events. Overall, two grade-3 serious AEs (Dengue fever and femur fracture) were reported and they are unrelated to study vaccine. Neutralizing Antibody titers, against both Ancestral and Delta strain, induced post two-dose vaccination regimen were higher in the CORBEVAX™ arm as compared to COVISHIELD™ and the analysis of GMT ratios demonstrated immunogenic superiority of CORBEVAX™ in comparison with COVISHIELD™. Both CORBEVAX™ and COVISHIELD™ vaccines showed comparable seroconversion post vaccination when assessed against anti-RBD IgG response. The subjects in CORBEVAX™ cohort also exhibited higher Interferon-gamma secreting PBMC’s post stimulation with SARS-COV-2 RBD peptides than the subjects in COVISHIELD™ cohort.
Interpretations Neutralizing antibody titers induced by CORBEVAX™ vaccine against Delta and Ancestral strains were protective, indicative of vaccine effectiveness of >90% for prevention of symptomatic infections based on the Correlates of Protection assessment performed during Moderna and Astra-Zeneca vaccine Phase III studies. Safety findings revealed that CORBEVAX™ vaccine has excellent safety profile when tested in larger and older population.
Funding BIRAC-division of Department of Biotechnology, Government of India, and the Coalition for Epidemic Preparedness Innovations funded the study.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
CTRI/2021/08/036074
Funding Statement
BIRAC- division of Department of Biotechnology, Government of India, and the Coalition for Epidemic Preparedness Innovations funded the study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Investigational Review Board or Ethics Committee at each study site approved the protocol. Centre- 1: Prakhar Hospital, Kanpur, approved on30 Aug 21 Centre- 2: GTB Hospital, Delhi, approved on 14 Sep 21 Centre- 3: ESIC Medical College & Hospital, Faridabad, approved on 30 Aug 21 Centre- 4: Shubham Sudbhawana Hospital, Varanasi, approved on 04 Sep 21 Centre- 5: St.Theresas Hospital (STH), Hyderabad, approved on 30 Aug 21 Centre- 6: KLES Dr. Prabhakar Kore Hospital & Medical Research Centre, Belgavi, approved on 03 Sep 21 Centre- 7: AIG Hospital, Hyderabad, approved on14 Sep 21 Centre- 8: Belgavi Institute of Medical Sciences, Belagavi, approved on 13 Sep 21 Centre- 9: National Institute of Medical Sciences (NIMS), Jaipur, approved on 11 Sep 21 Centre- 10: Grant Medical College & Sir J.J Hospital, Mumbai, approved on 13 Sep 21 Centre- 11: JLN Medical College, Ajmer, approved on 21 Sep 21 Centre- 12: Christian Medical College & Hospital, Ludhiana, approved on 25 Sep 21 Centre- 13: Apex Hospital, Jaipur, approved on 09 Sep 21 Centre- 14: Medanta Institute of Education and Research, Gurgaon, approved on 09 Sep 21 Centre- 15: BAPS Pramukh Swami Hospital, Surat06 Sep 21 Centre- 16: Christian Medical College Vellore Association, Vellore, approved on 30 Sep 21 Centre- 17: JSS Hospital, Mysuru, approved on 16 Sep 21 Centre- 18: Mahatma Gandhi Institute of Medical Sciences (MGIMS), Wardha, approved on 04 Sep 21 Centre- 19: All India Institute of Medical Sciences (AIIMS), Patna, approved on 09 Sep 21 Centre- 20: Samvedna Hospital, Varanasi, approved on 11 Sep 21
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Additional study data which is not part of the manuscript can be made available upon request and addressed to the corresponding author Dr. Subhash Thuluva at his email subhash.thuluva{at}biologicale.com.
